menu
    • menu

    Company profile for Adcendo

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Adcendo ApS is a Copenhagen-based biotech company dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the ADC approach to new levels through a focus on cancer-associated targets that are professional internalizers and allow for superior selectivity via highly preferential cancer expression. Adcendo has been part of BioInnovation Institute’s Creation House Program from mid 2019 unti...
    Adcendo ApS is a Copenhagen-based biotech company dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the ADC approach to new levels through a focus on cancer-associated targets that are professional internalizers and allow for superior selectivity via highly preferential cancer expression. Adcendo has been part of BioInnovation Institute’s Creation House Program from mid 2019 until closing of series A financing in April 2021.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AdcendoDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    BioInnovation Institute, Ole Maaløes Vej 3, Copenhagen, Capital Region of Den...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://adcendo.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/adcendo/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Adcendo Secures $75M In Series C Funding For Clinical ADC
    Adcendo Secures $75M In Series C Funding For Clinical ADC

    14 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first--and-best-in-class-clinical-adc-pipeline-302740749.html

    PR NEWSWIRE
    14 Apr 2026
    Share Share
    Adcendo Fast-Track Designated For ADCE-D01 in Soft Tissue Sarcoma
    Adcendo Fast-Track Designated For ADCE-D01 in Soft Tissue Sarcoma

    09 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adcendo-aps-announces-fda-fast-track-designation-granted-to-adce-d01-for-the-treatment-of-soft-tissue-sarcoma-302578882.html

    PR NEWSWIRE
    09 Oct 2025
    Share Share
    Adcendo ApS Begins Phase I/II ADCElerate1 Trial of ADCE-D01
    Adcendo ApS Begins Phase I/II ADCElerate1 Trial of ADCE-D01

    10 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adcendo-aps-announces-first-patient-dosed-in-phase-iii-adcelerate1-trial-of-adce-d01-302475071.html

    PR NEWSWIRE
    10 Jun 2025
    Share Share
    Adcendo ApS to Present Data on ADCs at 2025 AACR Meeting
    Adcendo ApS to Present Data on ADCs at 2025 AACR Meeting

    23 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adcendo-aps-to-present-data-on-its-clinical-stage-adcs-adce-t02-and-adce-d01-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting-302435250.html

    PR NEWSWIRE
    23 Apr 2025
    Share Share
    Adcendo ApS: Board Changes and Executive Team Strengthened
    Adcendo ApS: Board Changes and Executive Team Strengthened

    01 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adcendo-aps-announces-changes-in-board-of-directors-and-strengthens-executive-leadership-team-302416200.html

    PR NEWSWIRE
    01 Apr 2025
    Share Share
    Adcendo Announces FDA Clearance for Phase I Tiffany-01 Trial
    Adcendo Announces FDA Clearance for Phase I Tiffany-01 Trial

    26 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adcendo-aps-announces-us-fda-clearance-of-ind-application-for-phase-i-tiffany-01-trial-of-adce-t02-302384298.html

    PR NEWSWIRE
    26 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search